Price Band
₹540 - ₹570
Lot Size
26
Issue Size
₹3395 Cr
GMP
N/A
Subscription
67.42x
Analyzing...
IPO Schedule
1
Open
14 Jul 2025
2
Close
16 Jul 2025
3
Allotment
-
4
Listing
21 Jul 2025
About Anthem Biosciences
Anthem Biosciences is a contract research and manufacturing services (CRAMS) provider focused on the pharmaceutical and biotechnology industries. They offer a range of services, including drug discovery, development, and manufacturing, catering to both domestic and international clients.
Key Strengths
- Strong financial performance with consistent revenue growth and profitability.
- Experienced management team with a proven track record in the CRAMS industry.
- Diversified service offerings across the drug development and manufacturing value chain.
- Established relationships with leading pharmaceutical and biotechnology companies.
- Focus on innovation and technology adoption in its service delivery.
Risk Factors
- •Dependence on key clients, with a significant portion of revenue derived from a limited number of customers.
- •Exposure to regulatory risks and compliance requirements in the pharmaceutical industry.
- •Intense competition from other CRAMS providers, both domestic and international.
Valuation Analysis
The IPO is priced at a premium, reflected in the high P/E ratio, which may limit immediate upside potential for investors, especially given the competitive landscape.
IPO Details
ExchangeNSE
SegmentMAINBOARD
ISININE0CZ201020
NSE SymbolANTHEM
Face Value₹2
Lot Size26
Issue Size₹3395 Cr
Key Metrics
ROE20.1
ROCE24.5
P/E Ratio28.2
Industry P/E20
EPS8.07
PAT Margin23.38%
Debt/Equity0.38
Growth & Quality
ProfitableYes ✓
Subscription
Total0.77x
Imbalance Ratio7.6x
Documents
RHP not available
Key Dates
Open Date14 Jul 2025
Close Date16 Jul 2025
Listing21 Jul 2025